CJC-1295 isn't stocked on pharmacy shelves in Cadea or anywhere else for that matter — it's a research compound available through a dedicated online market. This global online supply model is actually an advantage for quality — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to evaluate CJC-1295 vendors rigorously — the standards covered in this guide are universal across all research contexts.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Cadea researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Assessing CJC-1295 vendors begins with the COA: locate the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone provides no identity confirmation. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that omit endotoxin testing. For Cadea researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Cadea
COA-verified · International tracking · Research grade
All use of CJC-1295 in Cadea or anywhere is research use only — this compound is not approved for therapeutic human application, and all handling should follow research laboratory protocols. Proper handling of CJC-1295 requires sterile reconstitution technique — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and consistent cold chain handling. The main safety concern arising from sourcing in CJC-1295 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the key safeguard. The research literature on CJC-1295 should be studied thoroughly before planning any study — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
